Split (1)

train · 22k rows

Record stringlengths 1 197k
* Phase 1: What does physical activity (intensity) mean to people with COPD?
* Phase 2: Are there differences between time spent in absolute and relative physical activity for people with COPD?
Phase 1 Participants will take part in semi-structured interview (30-45 minutes) about living with COPD and perceptions of physical activity and how they perceive intensity. This will also include photovoice and photo-elicitation. Demographic information will be recorded and participants will also complete several respiratory symptom questionnaires.
Phase 2:
Participants will take part in physical activity testing before and after pulmonary rehabilitation while wearing physical activity monitors. Demographic information will be recorded and participants will also complete several respiratory symptom and physical activity questionnaires. Participants will also wear the physical activity monitors for 8 days after the pre-testing sessions and after their final pulmonary rehabilitation class.
Sub-study:
Participants will be asked to take images of barriers during physical activity, facilitators during physical activity, feelings during physical activity and types of physical activity they take part in for 8 days after their final pulmonary rehabilitation class. Participants will then take part in a semi-structured interview about the images their have taken while doing physical activity. conditions: Chronic Obstructive Pulmonary Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 70 type: ESTIMATED measure: Phase 1 - Semi-structured Interviews measure: Phase 2 - Differences between time spent in PA intensity expressed in absolute and relative intensity. measure: Phase 1 - Medical Research Council (MRC) Dyspnoea Scale measure: Phase 1 - COPD Assessment Test (CAT) measure: Phase 1 - Chronic Respiratory Questionnaire (CRQ-SR) measure: Phase 1 - Photovoice and photo-elicitation measure: Phase 2 - Medical Research Council (MRC) Dyspnoea Scale measure: Phase 2 - COPD Assessment Test (CAT) measure: Phase 2 - Chronic Respiratory Questionnaire (CRQ-SR) measure: Phase 2 - Gait Analysis measure: Phase 2 - Exercise Capacity (ISWT) measure: Phase 2 - Exercise Capacity (ESWT) measure: Daily PROactive Physical Activity instrument in COPD (D-PPAC) measure: Phase 2 - Photovoice and photo-elicitation sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NIHR Leicester Biomedical Research Centre - Respiratory status: RECRUITING city: Leicester state: Leicestershire zip: LE67 2DU country: United Kingdom name: Phoebe H Lloyd-Evans role: CONTACT phone: +441162502758 email: phile1@leicester.ac.uk name: Mark W Orme role: CONTACT email: mwo4@leicester.ac.uk name: Mark W Orme role: PRINCIPAL_INVESTIGATOR lat: 52.6386 lon: -1.13169 hasResults: False
<\|newrecord\|> nctId: NCT06330610 id: 2021/0378/HP briefTitle: Evaluation of the Efficiency of Intermittent Enteral Nutrition on Multi-organ Failure From Patients With Mechanical Ventilation in Intensive Care Unit acronym: ENNUT-CI overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-06-01 date: 2027-08-01 date: 2024-03-26 date: 2024-03-26 name: University Hospital, Rouen class: OTHER briefSummary: This study aims to evaluate the efficiency of intermittent enteral nutrition versus continuous enteral nutrition to prevent from organ failures for patients at the acute phase of sepsis shock with mechanical ventilation in ICU. conditions: Intermittent Fasting conditions: Septic Shock conditions: Organ Failure, Multiple studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 174 type: ESTIMATED name: Intermittent enteral nutrition measure: Evolution of variation of the SOFA (Sepsis-related organ failure assessment) score. measure: evaluation of caloric intake measure: evaluation of protein intake measure: Measurement of nutritionnal status measure: Evaluation of the digestive symptoms measure: Evaluation of the nosocomial infections measure: Evaluation of the metabolic response measure: Evaluation of the duration of hospitalisation measure: Evaluation of the intensive care neuromuscular weakness measure: Evaluation of death measure: Evaluation of quality of life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06330597 id: 21-5196 briefTitle: NIVIA-Hemodynamics overallStatus: RECRUITING date: 2021-07-17 date: 2024-08-31 date: 2024-12-31 date: 2024-03-26 date: 2024-03-26 name: University Health Network, Toronto class: OTHER briefSummary: This is an investigator-initiated, single-center, single-arm prospective study to compare non-invasive hemodynamic assessment using transthoracic echocardiography (TTE) and lung ultrasound (LUS) and hemodynamic assessment using PAC. Patients who have been hemodynamically assessed using PAC will be invited to participate. Each patient will undergo TTE and LUS immediately after first invasive assessment, and again daily after PAC assessments. conditions: Cardiogenic Shock conditions: Heart Failure conditions: Shock conditions: Hemodynamic Instability studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Echocardiography and lung ultrasound measure: Correlation between E/e' ratio and PCWP vs. correlation between lung ultrasound score and PCWP. measure: Correlation between cardiac output measured by echocardiography (using LVOT diameter and VTI) and by PAC (using thermodilution) measure: Correlation between right atrial pressure assessed by echocardiography (using IVC diameter and respiratory variation) and by PAC measure: Correlation between pulmonary pressure assessed by echocardiography (using TR max velocity and estimated RAP) and by PAC measure: Correlation between pulmonary pressure assessed by echocardiography (using PAT) and by PAC measure: Correlation between PVR assessed by echocardiography (using PAT) and by PAC measure: Correlation between right ventricular function assessed by echocardiography (using TAPSE and S') and by PAC (using PAPI and RVSWI) measure: Correlation between E/e' ratio and PCWP vs. correlation between lung ultrasound score and PCWP. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Health Network status: RECRUITING city: Toronto state: Ontario zip: M5G 2N2 country: Canada name: Yishay Szekely, MD role: CONTACT phone: 4163404800 email: Yishay.szekely@uhn.ca lat: 43.70011 lon: -79.4163 hasResults: False
<\|newrecord\|> nctId: NCT06330584 id: AIM Care Study briefTitle: Administration of Intranasal Midazolam for Anxiety in Palliative Care acronym: AIM Care overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-10-31 date: 2024-10-31 date: 2024-03-26 date: 2024-03-26 name: Insel Gruppe AG, University Hospital Bern class: OTHER name: University Hospital, Basel, Switzerland name: University Hospital, Zürich name: Stadtspital Zürich briefSummary: The goal of this double-blind, randomized, placebo-controlled parallel-group multicenter exploratory pilot study (three study arms) is to describe effects and safety of different doses of intranasal midazolam to treat acute anxiety in palliative care patients, while providing pharmacokinetic and pharmacodynamic data. conditions: Anxiety conditions: Acute Anxiety studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Double-blind, randomized, placebo-controlled parallel-group multicenter exploratory pilot study with 3 study arms primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: All study personnel except the personnel at the facility preparing the investigational medicinal product (IMP) (Hospital Pharmacy, University Hospital Basel), and all patients will be blinded to the assigned treatment. Allocation will be concealed using sequentially coded drug packs (using consecutive patient identification numbers from 1 to at least 30) containing the IMP that are otherwise identical. Each drug pack will contain two nasal sprays of identical appearance. Patients and all trial personnel involved in recruitment and care of patients, trial assessment, monitoring, and analyses will be blinded to the assigned trial arm. Blinding will be upheld until the last patient (at least 30 patients, i.e., at least 10 per study arm) has completed the pilot study and data entry into the trial database has been completed.
To safeguard blinding, placebo formulation will be produced with the same pH as the active study drug formulations to mimic nasal irritation induced by verum sprays. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Placebo Nasal Spray 0 mg/spray name: Midazolam Nasal Spray 0.45 mg/spray name: Midazolam Nasal Spray 0.9 mg/spray measure: Change from baseline in anxiety levels, measured by Visual Analogue Scale (VAS) measure: Change from baseline in anxiety levels, measured by Numerical Rating Scale (NRS) measure: Sedation measure: Oxygen saturation SaO2 (percent %) measure: Heart rate (bpm) measure: Cortisol levels in oral fluid measure: Time to first requested additional dose measure: Cumulative number of doses over 24 hours measure: Number of patients with adverse drug events (ADEs) measure: Peak plasma concentration (Cmax) measure: Time to reach the peak plasma concentration (Tmax) measure: Elimination half-life (t1/2) measure: Area under the curve (AUC0-Τ, AUC0-∞) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Inselspital, Universitätsspital Bern city: Bern zip: 3010 country: Switzerland name: Manuel Haschke, MD role: CONTACT phone: +41 (0)31 632 67 93 email: manuel.haschke@insel.ch name: Manuel Haschke role: PRINCIPAL_INVESTIGATOR lat: 46.94809 lon: 7.44744 facility: Universitäres Zentrum für Palliative Care (UZP) city: Bern country: Switzerland name: Steffen Eychmüller, MD role: CONTACT phone: +41 (0)31 632 51 07 email: steffen.eychmueller@insel.ch lat: 46.94809 lon: 7.44744 facility: Zentrum für Palliative Care, Stadtspital Zürich city: Zürich zip: 8037 country: Switzerland name: Andreas Major, MD role: CONTACT phone: +41 (0)44 417 29 26 email: andreas.major@stadtspital.ch lat: 47.36667 lon: 8.54999 facility: Kompetenzzentrum Palliative Care, Universitätsspital Zürich city: Zürich zip: 8091 country: Switzerland name: Caroline Hertler, MD role: CONTACT phone: +41 (0)44 255 29 34 email: caroline.hertler@usz.ch lat: 47.36667 lon: 8.54999 hasResults: False
<\|newrecord\|> nctId: NCT06330571 id: Aligners in distalization briefTitle: The Efficiency of Clear Aligners in Maxillary Molar Distalization: A Randomized Clinical Trial. acronym: Aligner overallStatus: RECRUITING date: 2024-04-27 date: 2025-01-15 date: 2025-07-15 date: 2024-03-26 date: 2024-03-26 name: Ain Shams University class: OTHER briefSummary: The aim of this study is to evaluate the accuracy of clear aligners on the amount of the maxillary molar distalization. conditions: Orthodontic Aligners studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 10 type: ESTIMATED name: Molar distalization by aligners with attachment measure: Efficiency of aligners in molar distalization measure: Amount of anchorage loss measure: Amount of molar tipping sex: ALL minimumAge: 15 Years maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Ainshams university status: RECRUITING city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
<\|newrecord\|> nctId: NCT06330558 id: pheos briefTitle: Side-specific Factors for Conversion in Adrenalectomy for Pheochromocytoma. overallStatus: COMPLETED date: 2016-09-01 date: 2023-09-01 date: 2023-09-01 date: 2024-03-26 date: 2024-03-28 name: Zagazig University class: OTHER_GOV briefSummary: Context: Adrenalectomy for pheochromocytoma (PHEO) poses difficulties due to the elevated chance of conversion. The objective of this study was to conduct a comparative analysis of the occurrence and determinants of conversion in left-sided abdominal laparoscopic adrenalectomy (LLA) and right-sided abdominal laparoscopic adrenalectomy (RLA).
Methods: A retrospective analysis was conducted to include a total of 271 patients diagnosed with PHEO. These patients were separated into two groups: LRA (N=121) and LLA (N=150). The study period spanned from September 2016 to September 2023. conditions: Adrenal Tumor studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 271 type: ACTUAL name: laparoscopic right adrenalectomy measure: conversion sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06330545 id: STUDY02002161 briefTitle: Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2029-04 date: 2032-04 date: 2024-03-26 date: 2024-03-26 name: Dartmouth-Hitchcock Medical Center class: OTHER briefSummary: The goal of this study is to learn about preventing recurrence of Dupuytren's Contracture. The main question it aims to answer are:
• Does targeted radiation therapy decrease recurrence of Dupuytren's contracture after treatment with Collagenase Clostridium Histolyticum?
Participants will undergo:
* Release of Dupuytren's Contracture after Collagenase Clostridium Histolyticum injection
* Daily radiation therapy treatment for 5 days followed by 6-8 week rest period and then another course of 5 days of radiation therapy conditions: Dupuytren Contracture studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a prospective phase II trial where patients diagnosed with late/advanced stage Dupuytren's Contracture (DC) who undergo successful CCH injection and release will receive a standardized regimen of radiotherapy (RT). The study will be powered to assess the outcome in patients undergoing the combination of successful release followed by RT. Patients will be monitored for acute and late toxicities while we evaluate disease recurrence defined as a \> 20 degree worsening of contracture in the presence of a palpable cord, or the need for medical/surgical intervention to correct the new or worsening contracture. primaryPurpose: PREVENTION masking: NONE count: 95 type: ESTIMATED name: Radiation therapy measure: Recurrence of Dupuytren's Contracture measure: Radiation Toxicity measure: Patient Reported Outcomes after Radiation Treatment (RT) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06330532 id: 4-2023-1526 briefTitle: Impact of Preoperative Frailty and Cognitive Impairment on Postoperative Outcomes in Elderly Cardiac Surgery Patients overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-01 date: 2025-02-28 date: 2025-02-28 date: 2024-03-26 date: 2024-03-26 name: Yonsei University class: OTHER briefSummary: This is a retrospective study of patients aged 65 years and older who underwent cardiac and aortic surgery between March 5, 2021 and October 12, 2022 in the operating room of Severance Cardiovascular Hospital to determine the impact of physical frailty as well as nutritional status, emotional dysregulation, and cognitive dysfunction on postoperative outcomes. Physical frailty will be determined by the Clinical Frailty Scale, handgrip strength, and nutritional status, cognitive dysfunction will be determined by the K-MMSE and K-MoCA administered at the preoperative interview, and emotional dysregulation will be determined using the SGDS-K. These were measured during the pre-anesthesia evaluation and only results from patients who agreed to be tested will be used. Nutritional status will be analyzed based on blood test values measured within one month of surgery. conditions: Cardiovascular Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 450 type: ESTIMATED measure: postoperative all cause mortality measure: major composite morbidity measure: the number of days not in hospital measure: The number of participants who die sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Yonsei University Health system, Severance Hospital city: Seoul zip: 03722 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
<\|newrecord\|> nctId: NCT06330519 id: Ainshams University Dentistry briefTitle: Impact of Different Techniques on The Efficacy of Anaesthesia in Mandibular Molars With Acute Irreversible Pulpitis overallStatus: COMPLETED date: 2023-09-25 date: 2024-02-21 date: 2024-02-21 date: 2024-03-26 date: 2024-03-26 name: Ain Shams University class: OTHER briefSummary: The goal of this clinical trial is to assess the effect of
* Preoperative intraligamentary corticosteroids injection
* Cryotherapy which is cold application on :
* Hard tooth structure ( crown of the tooth )
* Soft tissue overlying roots on the efficacy of the inferior alveolar nerve block anaesthesia in patients with mandibular molars with symptomatic irreversible pulpitis. The main question it aims to answer are: • Does intraligamentary dexamethazone injection increase the success rate of inferior alveolar nerve block without the need for oral premedication.
Participants will describe their preoperative pain level to the investigator and describe their pain level during the treatment.
Researchers will compare cryotherapy to see if it increases the success rate of inferior alveolar nerve block. conditions: Pulpitis - Irreversible studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 72 type: ACTUAL name: Dexamethasone sodium phosphate injection name: 1,1,1,2 tetrafluoroethane name: intraoral soft tissue cryotherapy measure: The effect of intraligamentary dexamethazone injection on the success rate of inferior alveolar nerve block sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Ain Shams University city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
<\|newrecord\|> nctId: NCT06330506 id: 123456123456 briefTitle: The Effect of Pressure Ulcer Care Package on the Risk of Pressure Ulcer Development overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2024-08-10 date: 2024-09-10 date: 2024-03-26 date: 2024-03-26 name: Cukurova University class: OTHER briefSummary: This study aimed to determine the effect of pressure ulcer care package use on the risk of pressure ulcer development due to surgery in patients undergoing orthopedic surgery. It was planned as a randomized controlled study. The population of the study will consist of patients who underwent surgery in the Orthopaedics and Traumatology Clinic of Doğubayazıt Dr.Yaşar Eryılmaz State Hospital Hospital Hospital of Ağrı Provincial Health Directorate. The sample of the study will consist of patients who volunteered to participate in the study that meets the inclusion criteria. To obtain research data, the Personal Information Form developed by the researcher in line with the literature, 3S Operating Theatre Pressure Wound Risk Assessment Scale, Pressure Wound Regions and Stages Monitoring Form prepared according to NPUAP (2016) Pressure Wound Staging System Form will be used. Statistical analysis of the data obtained from the study will be performed using the SPSS 25 (Statistical Package of Social Science) package program. conditions: Pressure Ulcer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 102 type: ESTIMATED name: Pressure ulcer prevention pack measure: Evaluation of pressure ulcer formation sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06330493 id: AcoArt BTK Global Trial briefTitle: AcoArt Litos PCB Below-the-knee Global Trial overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-10 date: 2030-12 date: 2024-03-26 date: 2024-04-29 name: Acotec Scientific Co., Ltd class: INDUSTRY briefSummary: The objective of this study is to assess whether efficacy of the AcoArt Litos PCB is superior and whether safety of AcoArt Litos PCB is noninferior to the control device (FDA cleared PTA Balloon Catheter) regarding treatment of obstructions in the infrapopliteal arteries (located distal to the P3 segment of the popliteal artery and extending to the tibiotalar joint) in patients presenting with chronic limb-threatening ischemia (CLTI)(Rutherford 4-5) conditions: Chronic Limb-Threatening Ischemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 288 type: ESTIMATED name: PCB name: PTA measure: Primary Efficacy Endpoint: Composite of freedom from major amputation and primary patency measure: Primary Safety Endpoint: Composite of MALE and POD (Major Adverse Limb Event + Peri-Operative Death) measure: Composite of Limb Salvage and Primary Patency measure: Patency rate measure: Freedom from CD-TLR measure: Re-occlusion rate of target lesion measure: Rate of Major adverse events(MAE) measure: Rate of target limb major amputation measure: Rate of all-cause death measure: Amputation free survival rate measure: Change in ankle-brachial index(ABI) measure: Change in toe-brachial index(TBI) measure: Change in Rutherford category measure: Change in EQ-5D measure: Change in VascuQol measure: Primary sustained clinical improvement measure: Secondary sustained clinical improvement measure: Wound healing measure: Rate of Device Success measure: Rate of Technical Success measure: Rate of Procedure Success sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06330480 id: Check@Home briefTitle: Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2027-11-01 date: 2028-11-01 date: 2024-03-26 date: 2024-03-26 name: Prof. Dr. Folkert W. Asselbergs class: OTHER name: Dutch Cardiovascular Alliance name: University Medical Center Groningen name: Dutch Heart Foundation name: Dutch Kidney Foundation name: Dutch Diabetes Research Foundation name: Maastricht University name: AstraZeneca BV name: UMC Utrecht name: Radboud University Medical Center name: Siemens Healthineers Nederland BV name: University of Twente name: Roche Diagnostics Nederland BV name: Luscii healthtech BV name: Happitech BV name: Stichting Radboud Universiteit name: Stichting Netherlands Heart Institute briefSummary: The aim of the Check@Home consortium is to set up a roadmap and infrastructure for a program to early detect atrial fibrillation and chronic kidney disease in the general population.
This will be a population-based screening with a phased implementation and an iterative design in four regions in the Netherlands (Breda, Utrecht, Arnhem, Eindhoven). In total, a random sample of 160,000 people (aged 50-75 years) will be invited to participate in the study and another random sample of 160,000 people with the same characteristics will be included in the control group in which no screening will be offered.
The overall screening program will consist of three phases: a home-based testing phase, diagnostic screening phase, and a treatment phase:
* Phase 1: Subjects will be invited for a home-based screening that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement using a smartphone app for detection of atrial fibrillation.
* Phase 2: Depending on the results on these home-based tests, subjects will be invited for further screening in a diagnostic screening facility. During this visit, physical data will be collected (height, weight, waist circumference, blood pressure, heart rhythm), blood will be drawn, and urine will be collected for the assessment of parameters that are indicative of a cardiovascular disease, chronic kidney disease, type 2 diabetes or their risk factors. Participants will receive a questionnaire that include questions on demographics, educational level, disease history, medication use, health literacy, and quality of life.
* Phase 3: Based on the results of the diagnostic screening, participants may be referred to their general practitioner for appropriate treatment (lifestyle advice/medication) according to the prevailing guidelines.
The primary study outcomes are:
Overall effectiveness of population based screening on atrial fibrillation and chronic kidney disease in subjects aged 50-75 years, based on:
* Participation rate of different screening strategies and phases;
* Yield of the screening (number of subjects with (newly) diagnosed disease and risk factors);
* Effectiveness of the atrial fibrillation screening, compared with standard care, based on the incidence of ischemic stroke);
* Effectiveness of the albuminuria screening, compared with standard care, based on the incidence of kidney failure events and Major Adverse Cardiovascular Events (MACE). conditions: Atrial Fibrillation conditions: Chronic Kidney Diseases conditions: Diabetes Mellitus, Type 2 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Check@Home is a population-based screening with a phased assessment and implementation using an iterative design executed consecutively in four regions in the Netherlands. primaryPurpose: SCREENING masking: NONE count: 320000 type: ESTIMATED name: Intervention group measure: Participation rate of the atrial fibrillation and albuminuria screening measure: Yield of the atrial fibrillation and albuminuria screening measure: Effectiveness of the atrial fibrillation screening measure: Effectiveness of the albuminuria screening measure: Effectiveness of the atrial fibrillation screening based on incidence of MACE events measure: Effectiveness of the albuminuria screening based on incidence each individual MACE component measure: Safety of the atrial fibrillation screening measure: Cost-effectiveness of screening strategies compared with standard of care: treatment effectiveness based on literature. measure: Cost-effectiveness of screening strategies compared to standard of care: treatment effectiveness based on actual observed event rates measure: False-positive rate, false-negative rate, sensitivity, specificity, positive predictive screening on atrial fibrillation and albuminuria screening. measure: Characteristics of responders and non-responders measure: Effectiveness of the atrial fibrillation screening based on incidence each individual MACE component measure: Overall effectiveness of broader population-based screening strategies applied to screening on heart failure, coronary artery disease, and type 2 diabetes. sex: ALL minimumAge: 50 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06330467 id: 2023-A02442-43 id: RIPH 2023-02 type: REGISTRY domain: sponsor's internal reference briefTitle: Prevalence of Dissociative Identity Disorder in At-risk Outpatient Groups Reporting Childhood Trauma. acronym: IDENTITY overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-03-31 date: 2026-06-30 date: 2024-03-26 date: 2024-03-28 name: Centre Psychothérapique de Nancy class: OTHER briefSummary: The investigators will study the prevalence of dissociative identity disorder (DID) in three populations at risk in cases of childhood psychotrauma : patients with a diagnosis of borderline personality, patients with a diagnosis of functional dissociative crises (FDC) and patients with early psychosis.
The investigators will also study the prevalence of other dissociative disorders and the frequency of complex post-traumatic stress disorder.
The investigators will also look for correlations between the type of maltreatment in childhood, the age of onset of trauma and the type of diagnosis of dissociative disorders.
The investigators hope to include 150 borderline patients, 150 FDC patients and 50 early psychosis patients.
Data collection will be done via a psychometric administration of 7 self-completion questionnaires as well as the completion of the SCID-D semi-structured interview. conditions: Dissociative Disorder studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 3 groups : borderline, early psychosis and FDC. primaryPurpose: DIAGNOSTIC masking: NONE count: 350 type: ESTIMATED name: psychometric assessment name: semi-structured clinical interview measure: SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders / DSM = Diagnostic and Statistical Manual of Mental Disorders / ICD = International Classification of Diseases measure: SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders measure: CTQ-28 : Childhood Trauma Questionnaire measure: life events inventory DSM-5 measure: PCL-5 : Posttraumatic stress disorder CheckList-5 measure: ITQ : International Trauma Questionnaire measure: SDQ-20 : Somatoform Dissociative questionnaire measure: DIS-Q : Dissociation Questionnaire measure: DES : Dissociative Experience Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Psychothérapique de Nancy - CLIP city: Nancy country: France name: Vincent LAPRÉVOTE role: CONTACT email: vincent.laprevote@cpn-laxou.com name: Vincent LAPRÉVOTE role: PRINCIPAL_INVESTIGATOR name: Lori PETROCELLI role: SUB_INVESTIGATOR lat: 48.68439 lon: 6.18496 facility: Centre Psychothérapique de Nancy - CMP Jacquard et Des Près city: Nancy country: France name: Coraline HINGRAY role: CONTACT email: coraline.hingray@cpn-laxou.com name: Coraline HINGRAY role: PRINCIPAL_INVESTIGATOR name: Lori PETROCELLI role: SUB_INVESTIGATOR lat: 48.68439 lon: 6.18496 facility: CHRU Nancy - Neurology department city: Nancy country: France name: Coraline HINGRAY role: CONTACT email: coraline.hingray@cpn-laxou.com name: Coraline HINGRAY role: PRINCIPAL_INVESTIGATOR name: Alexis TARRADA role: SUB_INVESTIGATOR name: Séverine CONRADI role: SUB_INVESTIGATOR name: Lori PETROCELLI role: SUB_INVESTIGATOR lat: 48.68439 lon: 6.18496 hasResults: False
<\|newrecord\|> nctId: NCT06330454 id: 483/2020/Disp/AOUFe briefTitle: Painful Total Knee Replacement (TKA) and I-one Therapy overallStatus: RECRUITING date: 2020-10-22 date: 2025-10-21 date: 2025-10-21 date: 2024-03-26 date: 2024-03-28 name: University Hospital of Ferrara class: OTHER briefSummary: Arthroplasty operations are very frequent and their number is constantly increasing. The success of prosthetic surgery is linked to surgical factors (prosthesis type, prosthesis design, prosthesis material, surgical hand) and 'biological' factors (inflammation, pain, oedema, impingement). It is well known that important functional limitations may result mainly from an overreaction involving the peri-articular tissues. This is particularly true after total knee arthroplasty (TKA) surgery, during which a large part of the bone tissue and part of the peri-articular tissues (joint capsule, ligaments, synovium) are dislodged or removed. In the days following arthroplasty operations, the presence of a strong local inflammatory component is associated with pain and functional limitation, which usually resolves within a few months; however, it can sometimes take longer, and sometimes result in a chronic, albeit modest, inflammatory condition that lasts for years. There is still a percentage of 11-25% of patients who remain not completely satisfied with the result achieved with prosthetic surgery . Baker et al. state that 19.8% of patients experience pain one year after arthroplasty . Beswick et al. report that many patients (10-34%) continue to experience significant pain and functional limitation after arthroplasty even years later. conditions: Knee Pain Swelling studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 237 type: ESTIMATED name: I-ONE measure: Evaluate pain resolution after treatment with I-ONE® therapy in patients with painful TKA at least 1 month after surgery. measure: reduced NSAID intake measure: improved recovery of joint function sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Istituto Ortopedico Rizzoli status: RECRUITING city: Bologna state: BO country: Italy name: Francesco Traina role: CONTACT lat: 44.49381 lon: 11.33875 facility: Poliambulanza Brescia status: RECRUITING city: Brescia state: BS country: Italy name: Francesco Benazzo role: CONTACT lat: 45.53558 lon: 10.21472 facility: Policlinico San Matteo Pavia status: RECRUITING city: Pavia state: PV country: Italy name: Mario Mosconi role: CONTACT lat: 45.19205 lon: 9.15917 facility: Ospedale Mauriziano Torino status: RECRUITING city: Torino state: TO country: Italy name: Roberto Rossi role: CONTACT lat: 45.07049 lon: 7.68682 facility: Ospedale Sacro Cuore Don Calabria Negrar Verona status: RECRUITING city: Negrar state: VR country: Italy name: Claudio Zorzi role: CONTACT lat: 45.52918 lon: 10.93899 facility: Policlinico di Bari status: RECRUITING city: Bari country: Italy name: Biagio Moretti role: CONTACT lat: 41.11148 lon: 16.8554 facility: Ospedale Santo Spirito in Sassia/Ospedale San Filippo Neri Roma status: RECRUITING city: Roma country: Italy name: Francesco Falez role: CONTACT lat: 41.89193 lon: 12.51133 hasResults: False
<\|newrecord\|> nctId: NCT06330441 id: MOU-2021-01 briefTitle: Pancreatic Cancer Screening in a Population at High Risk acronym: ScrePan overallStatus: RECRUITING date: 2022-01-07 date: 2025-01-06 date: 2028-01-06 date: 2024-03-26 date: 2024-04-01 name: Masaryk Memorial Cancer Institute class: OTHER name: Masaryk University briefSummary: Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing. In a certain proportion of patients, it is possible to predict the disease, e.g. due to family burdens. Regular follow-up of such individuals is the subject of the SCREPAN study: "Pancreatic Cancer Screening in High-Risk Persons". conditions: Pancreatic Ductal Adenocarcinoma conditions: Hereditary Diseases conditions: Pancreatitis, Chronic studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: SCREENING masking: SINGLE whoMasked: PARTICIPANT count: 700 type: ESTIMATED name: endoscopic ultrasonography name: magnetic resonance name: laboratory examination measure: Number of participants with newly diagnosed pancreatic ductal adenocarcinoma measure: Methods yield comparison measure: Screening methods cost-effectiveness measure: KRAS mutation status evaluation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Masaryk Memorial Cancer Institute status: RECRUITING city: Brno zip: 65653 country: Czechia name: Martina Lojova, Ph.D. role: CONTACT phone: +420543136232 email: martina.lojova@mou.cz name: Dita Kozakova, Ing. role: CONTACT phone: +420543136236 email: dita.kozakova@mou.cz name: Petr Karasek, MD role: PRINCIPAL_INVESTIGATOR name: Jana Halamkova, MD role: SUB_INVESTIGATOR name: Helena Coupkova, MD role: SUB_INVESTIGATOR name: Anna Ondrackova, MD role: SUB_INVESTIGATOR name: Marketa Palacova, MD role: SUB_INVESTIGATOR name: Radim Nemecek, MD role: SUB_INVESTIGATOR name: Lumir Kunovsky, MD role: SUB_INVESTIGATOR name: Jan Trna, MD role: SUB_INVESTIGATOR name: Lenka Foretova, MD role: SUB_INVESTIGATOR name: Zdenka Cermakova, MD role: SUB_INVESTIGATOR name: Jan Kristek, MD role: SUB_INVESTIGATOR name: Roman Hrstka, Ph.D. role: SUB_INVESTIGATOR lat: 49.19522 lon: 16.60796 hasResults: False
<\|newrecord\|> nctId: NCT06330428 id: MU-Ebe-ZDKY-02 briefTitle: Investigation of the Effect of Sexuality-Based Family Planning Education Given to Women Via Podcast on Contraceptive Method Selection and Sexual Life Quality overallStatus: RECRUITING date: 2024-02-09 date: 2024-06-10 date: 2024-08-10 date: 2024-03-26 date: 2024-03-26 name: Marmara University class: OTHER briefSummary: In this study, it was aimed to examine the effect of Sexuality-Based Family Planning Education given to women of childbearing age via Podcast on contraceptive method selection and sexual life quality.
Accordingly, the hypotheses of the study are as follows:
Hypotheses of the Project H1: Sexuality-based family planning education via podcast has an effect on women's conscious and appropriate contraceptive method selection.
H2: Sexuality-based family planning education via podcast has a positive effect on women's sexual life quality.
H3: Sexuality-based family planning education via podcast has a positive effect on the quality of sexual life of women by increasing their level of contraceptive knowledge.
H4: Sexuality-based family planning education via podcast has a positive effect on women's attitudes towards family planning. conditions: Contraception studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: One control group, one experimental group primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: The experimental group will receive sexuality-based family planning education via podcast and outcome assessment will be performed by an investigator who was blinded to group assignment. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 176 type: ESTIMATED name: Sexuality-Based Family Planning Education via Podcast measure: Contraceptive Knowledge Assessment Scale-Turkish Form measure: Sexual Quality of Life Scale-Female measure: Family Planning Attitudes Scale sex: FEMALE minimumAge: 15 Years maximumAge: 49 Years stdAges: CHILD stdAges: ADULT facility: Marmara University status: RECRUITING city: Istanbul country: Turkey name: Meltem Demirgöz Bal role: CONTACT phone: +905056482983 email: meltemdemirgoz@gmail.com lat: 41.01384 lon: 28.94966 hasResults: False
<\|newrecord\|> nctId: NCT06330415 id: 25603 briefTitle: Effect and Process Evaluation of the SME Tool overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-08-01 date: 2024-03-26 date: 2024-03-26 name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) class: OTHER name: ZonMw: The Netherlands Organisation for Health Research and Development briefSummary: A web-based tool has been developed to help small and medium-sized businesses support employees returning to work after sick-leave. A six-month trial is conducted, randomly assigning employer-employee dyads to either use the tool or receive standard care. The primary aim is to evaluate its impact on employee satisfaction with return-to-work support. conditions: Sick-listed Employees studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 404 type: ESTIMATED name: The SME tool measure: Satisfaction with the RTW support of employer assessed by the employee measure: Social support measure: Total number of sick-leave days measure: Work performance measure: Quality of working Life measure: Self-efficacy measure: Satisfaction with the resumption of work of the respective employee measure: Recruitment measure: Use of the SME tool measure: Perceived usefulness of the SME tool measure: Components of the logic model of change measure: Experiences sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06330402 id: N-20220063 briefTitle: Exploration of Gait Biomechanics and Pain overallStatus: RECRUITING date: 2023-09-26 date: 2026-12-31 date: 2026-12-31 date: 2024-03-26 date: 2024-03-26 name: Kristian Kjær Petersen class: OTHER briefSummary: This interventional study aims to test gait biomechanics in healthy individuals with and without experimental knee pain. The main questions it aims to answer are:
* How do gait patterns change during painful walking?
* Can pain sensitivity testing and gait biomechanics predict experimental knee pain intensity?
Participants will receive two knee injections: a) Hypertonic saline (painful condition) and b) Isotonic saline (control condition). conditions: Pain conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: SINGLE whoMasked: PARTICIPANT count: 34 type: ESTIMATED name: Hypertonic saline injection name: Isotonic saline injection measure: Infrared marker XYZ coordinates measure: Pain sensitivity. measure: The Pittsburgh Sleep Quality Index score measure: The Pain catastrophizing Scale score measure: The Hospital Anxiety and Depression Scale measure: Knee symptoms measure: Ground reaction forces measure: Ground reaction moments measure: Ground contact XZ location measure: Muscle activation measure: Pain intensity (NRS 0-10) measure: Pain distribution sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Aalborg University status: RECRUITING city: Aalborg state: Nordjylland zip: 9000 country: Denmark name: Kristian K Petersen, Dr. Med role: CONTACT phone: (+45) 31697510 email: kkp@hst.aau.dk name: Emma Hertel, M. Sc. role: CONTACT phone: (+45) 60887473 email: eh@hst.aau.dk lat: 57.048 lon: 9.9187 hasResults: False
<\|newrecord\|> nctId: NCT06330389 id: MRC-01-20-1074 briefTitle: Burn Injuries During COVID-19 Pandemic and Its Influence on Length of Stay overallStatus: COMPLETED date: 2020-04-01 date: 2021-03-01 date: 2021-06-25 date: 2024-03-26 date: 2024-03-26 name: Hamad Medical Corporation class: INDUSTRY briefSummary: Burn injuries were thought to be difficult to treat during the new corona virus epidemic. Our goal is to determine the risk factors that influence length of hospital stay (LOS) of burn injured patients during COVID -19 pandemic. conditions: SARS-CoV-2 Infection studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 70 type: ACTUAL name: Burn Injuries Graft Surgery measure: Our goal is to determine the risk factors that influence length of hospital stay (LOS) of burn injured patients during COVID -19 pandemic. measure: Clinical diffreneces between burn injuries with positive vs negative COVID-19 status sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: HAMAD Medical Corporation- Al Wakra Hospital city: Doha zip: 82228 country: Qatar lat: 25.28545 lon: 51.53096 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2020-05-30 uploadDate: 2021-09-07T14:07 filename: Prot_SAP_000.pdf size: 273860 hasResults: False
<\|newrecord\|> nctId: NCT06330376 id: PT-2022-30735 briefTitle: Diaphragmatic Breathing Exercises for Post-COVID-19 Diaphragmatic Dysfunction (DD) overallStatus: RECRUITING date: 2024-03-01 date: 2024-06-01 date: 2024-09-01 date: 2024-03-26 date: 2024-04-05 name: University of Minnesota class: OTHER briefSummary: Diaphragm is the principal muscle of inspiration. Diaphragmatic dysfunction is seen in many conditions including following intubation, lung disease, prolonged ventilation, neuromuscular disease, phrenic nerve injury. The possible mechanisms of diaphragmatic dysfunction in patients with COVID19 are critical illness myopathy, ventilator-induced diaphragm dysfunction, iatrogenic phrenic nerve injury particularly secondary to line placement, post-infectious inflammatory neuropathy of the phrenic nerve, or possibly direct neuromuscular involvement of the SARS- CoV-2 virus given expression of the angiotensin- converting enzyme 2 (ACE2) receptor in the peripheral nervous system and skeletal muscle. The use of diaphragmatic ultrasound has been widely used to assess diaphragmatic function is well known in patients following prolonged mechanical ventilation. Prolonged mechanical ventilation leads to contractile dysfunction of respiratory muscles, in particular the diaphragm, causing a so-called ventilator-induced diaphragm dysfunction. The latter is defined as a loss of diaphragm force-generating capacity specifically related to the use of mechanical ventilation. However, the use of diaphragmatic Ultrasound to assess its function in Long COVID patients has not been noted and is a gap in the work up of these patients.
The purpose of this study is to address Diaphragmatic Dysfunctional (DD) breathing seen in patients with Post-Acute Sequelae of COVID-19 (PASC), which results in shortness of breath/chest tightness and subsequent fatigue. Targeting shortness of breath and subsequent fatigue as a central symptom of PASC will alleviate long term sequelae for the patients with PASC. DD will be addressed by a unique intervention of physical therapy. The goal of this prospective randomized clinical study will be to evaluate the comparative treatment effect of DB on markers, specifically fatigue, dyspnea, 6 min walk test, depression/anxiety, and quality of life (QoL). conditions: Post-Acute Sequelae of COVID-19 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: prospective randomized clinical study with 2 arms primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Usual care of traditional treatment name: Specific DB program/Diaphragmatic manipulation program measure: 6-minute walk test (6MWT) measure: PHQ9: Patient health questionnaire 9 measure: GAD7: Generalized anxiety disorder 7-item measure: PROMIS score: Patient-Reported Outcomes Measurement Information System measure: QoL scale: Quality of life scale measure: FACIT fatigue scale 's Fatigue score measure: Modified Borg dyspnea scale measure: RR; respiratory rate with 6 min walk test measure: PR: pulse rate with 6 min walk test sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Minnesota status: RECRUITING city: Minneapolis state: Minnesota zip: 55414 country: United States name: Farah Ikramuddin role: CONTACT email: ikram002@umn.edu lat: 44.97997 lon: -93.26384 hasResults: False
<\|newrecord\|> nctId: NCT06330363 id: METC 23-049 briefTitle: The Impact of Low Level Laser Treatment on Skeletal Muscle and Skin Tissue acronym: LASER overallStatus: RECRUITING date: 2024-04-01 date: 2024-08-31 date: 2024-12-31 date: 2024-03-26 date: 2024-04-17 name: Maastricht University Medical Center class: OTHER briefSummary: Rationale: Low level laser therapy, or photobiomodulation, is getting more attention as a non-invasive treatment strategy for numerous conditions. Phototherapy has been applied for more than 40 years for the treatment of musculoskeletal and neurological conditions. Low level laser therapy generally applies red or near-infrared lasers with a wavelength between 600 and 1000 nm and low power wattage from 5 to 500 mW and a power density between 1 and 5 W/cm2. The laser light is absorbed by the skin without thermal damage and penetrates deeply into tissues where it is supposed to induce its physiological effects at the cellular level. Laser therapy has been hypothesized to stimulate mitochondrial respiration, increase tissue oxygenation, and support tissue regeneration. Despite supportive research data on in vitro cell and in vivo animal data, there are surprisingly few data on the proposed impact of low level laser treatment (LLLT) on tissue metabolism in vivo in humans.
Objective: To assess the impact of acute laser treatment on muscle tissue mitochondrial respiration in vivo in healthy, young adults. Secondary objectives include the in vivo assessment of cellular energy, anabolic, angiogenic and inflammatory pathways, along with enzyme activity within muscle and skin.
Study design: Within-subject study.
Study population: 12 healthy (BMI 18.5-30 kg/m2) young (age: 18-35 y) adults (6 men and 6 women).
Intervention: One leg of the subjects will receive LLLT, while the other leg will receive no treatment. After the treatment muscle and skin biopsy samples will be taken from both legs.
Main study parameters/endpoints: The primary outcome will be mitochondrial respiration of the LLLT treated and non-treated leg based on muscle samples. Secondary study parameters are muscle and skin gene expression, protein signalling and enzyme activity. conditions: Muscles Metabolism conditions: Skin Metabolism studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Within-subject study primaryPurpose: BASIC_SCIENCE masking: DOUBLE maskingDescription: One let will receive the laser therapy, the other one will get a sham laser. The person analyzing the samples will be blinded to legs. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 16 type: ESTIMATED name: Laser therapy name: Sham measure: Muscle mitochondrial respiration measure: Gene expression (mRNA) via real-time PCR measure: Protein expression via western blotting measure: Skin mitochondrial respiration sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Maastricht University Medical Centre status: RECRUITING city: Maastricht country: Netherlands name: Luc JC van Loon, PhD role: CONTACT phone: +31-43-3881397 email: l.vanloon@maastrichtuniversity.nl lat: 50.84833 lon: 5.68889 hasResults: False
<\|newrecord\|> nctId: NCT06330350 id: METC 2023-0193 briefTitle: Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling overallStatus: RECRUITING date: 2024-01-01 date: 2025-08-31 date: 2025-12-31 date: 2024-03-26 date: 2024-03-26 name: Maastricht University Medical Center class: OTHER briefSummary: The goal of this observational study is to understand the perspectives and needs of patients with genodermatoses and their partners who wish to have children, regarding their decision-making process and their consideration of reproductive options. Additionally, the investigators aim to investigate the level of knowledge and perspectives of healthcare professionals (such as clinical geneticists, dermatologists and other clinicians involved), and want to explore to what extent patients and their partners are well informed about these reproductive options. To achieve this, the investigators will conduct individual semi-structured qualitative interviews with participants affected by genodermatoses (and their partners) and with healthcare professionals. conditions: Quality of Life conditions: Ichthyosis conditions: Palmoplantar Keratoses conditions: Epidermolysis Bullosa conditions: Ectodermal Dysplasia conditions: Basal Cell Nevus Syndrome conditions: Birt-Hogg-Dube Syndrome conditions: Tuberous Sclerosis conditions: Cutis Laxa conditions: Albinism studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: Qualitative interview measure: Assessment of perspectives of affected patients + partners and of healthcare professionals concerning reproductive decision-making sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Maastricht University Medical Center status: RECRUITING city: Maastricht state: Limburg zip: 6202 AZ country: Netherlands name: Fauve C van Veen role: CONTACT phone: +31433877293 email: genodermatose@mumc.nl lat: 50.84833 lon: 5.68889 hasResults: False
<\|newrecord\|> nctId: NCT06330337 id: ZSLL-KY-2024-010-01 briefTitle: Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma overallStatus: RECRUITING date: 2024-04-01 date: 2026-12-31 date: 2027-12-31 date: 2024-03-26 date: 2024-03-26 name: The Third Affiliated hospital of Zhejiang Chinese Medical University class: OTHER name: Zhejiang University briefSummary: Gliomas are the most common type of primary brain tumors, with surgery followed by radiotherapy and chemotherapy as the main treatment modalities. However, they are highly prone to recurrence, presenting significant treatment challenges, especially for high-grade gliomas, which have a 5-year survival rate of only 5.5%. Paclitaxel, a common chemotherapeutic agent, exhibits antitumor effects in vitro that are 1400 times stronger than those of temozolomide (the first-line chemotherapy drug for gliomas). However, due to its large molecular weight (approximately 893 Da), it cannot cross the blood-brain barrier, precluding its use as a first-line treatment for gliomas. Preliminary research by our team has demonstrated that Specific Mode Electroacupuncture Stimulation (SMES) can open the blood-brain barrier, enhancing the concentration of albumin-bound paclitaxel (ABX) in tumor tissues, peritumoral tissues, and surrounding invasive tissues, thereby exerting antitumor effects. Consequently, this study aims to observe the safety and efficacy of SMES combined with ABX in treating patients with recurrent high-grade gliomas postoperatively, to explore its mechanisms of action, extend survival, improve quality of life, and forge new theories and methods for the integrative treatment of brain tumors combining traditional Chinese and Western medicine. conditions: Glioma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 58 type: ESTIMATED name: Temozolomide（TMZ） injection or oral administration name: Albumin-Bound Paclitaxel(ABX) intravenous drip name: Specific mode electroacupuncture stimulation(SMES) intervention measure: Overall survival（OS） measure: Progression-Free Survival (PFS) measure: Head MRI (plain and enhanced) measure: he Karnofsky Performance Score (KPS) measure: The Eastern Cooperative Oncology Group (ECOG) measure: The Quality of Life (QOL) measure: The Neurological Assessment for Neuro-Oncology (NANO) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Third Affiliated Hospital of Zhejiang Chinese Medical University status: RECRUITING city: Zhejiang country: China name: Xianming Lin, PHD role: CONTACT phone: +86-13858028101 email: linxianming1966@163.com name: Zhaoxing Jia, PHD role: CONTACT phone: +86-18356130598 email: zhenxinzhenyi183@163.com hasResults: False
<\|newrecord\|> nctId: NCT06330324 id: METC 2023-0182 briefTitle: Reproductive Options in Inherited Skin Diseases acronym: REPRO-ISD overallStatus: ENROLLING_BY_INVITATION date: 2024-01-01 date: 2026-09-01 date: 2026-09-01 date: 2024-03-26 date: 2024-03-26 name: Maastricht University Medical Center class: OTHER briefSummary: The goal of this observational study is to learn about the indications for prenatal diagnostics and preimplantation genetic testing for patients/couples affected by an inherited skin disease, and evaluate the clinical outcomes of these reproductive options. By providing a complete overview, the investigators aim to improve reproductive counselling for these patients/couples with a desire to have children.
To achieve this, the investigators aim to retrospectively collect data from a cohort of patiens/couples affected by an inherited skin disease on a national level (in the Netherlands) and also an international level from various countries in Europe. conditions: Ichthyosis conditions: Palmoplantar Keratoses conditions: Epidermolysis Bullosa conditions: Ectodermal Dysplasia conditions: Basal Cell Nevus Syndrome conditions: Birt-Hogg-Dube Syndrome conditions: Tuberous Sclerosis conditions: Xeroderma Pigmentosum conditions: Cutis Laxa conditions: Albinism studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 650 type: ESTIMATED measure: Assessment of clinical outcomes of reproductive options sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Maastricht University Medical Center city: Maastricht state: Limburg zip: 6202AZ country: Netherlands lat: 50.84833 lon: 5.68889 hasResults: False
<\|newrecord\|> nctId: NCT06330311 id: 20/551-EC briefTitle: Effectiveness of Whole-Body Vibration acronym: WBVibration overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-29 date: 2024-09-29 date: 2024-09-29 date: 2024-03-26 date: 2024-04-12 name: Universidad Complutense de Madrid class: OTHER name: Hospital Infantil Universitario Niño Jesús, Madrid, Spain briefSummary: Cerebral Palsy is the most common cause of severe physical disability in childhood and may present difficulties and limitations that will have an impact on their independence and integration in all social areas.
Within interventions aiming to manage CP Whole-Body Vibration (WBV) has shown some benefits such as reducing spasticity or improving strength and functionality of the lower limbs.
The aim of this study is to assess the effectiveness on motor function and spasticity of the lower limbs by adding an intervention with WBV to an evidence-based multimodal physiotherapy treatment in children with CP. conditions: Spastic Cerebral Palsy conditions: Physical Therapy Modalities conditions: Vibration; Exposure conditions: Lower Extremity Weakness, Spastic conditions: Muscle Spasticity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The participants will be randomly allocated to experimental or control group primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The principal investigator will be blinded to the randomization, patient assessment, and data analysis. whoMasked: INVESTIGATOR count: 30 type: ACTUAL name: Physiotherapy measure: GROSS MOTOR FUNCTION MEASURE 88 (D and E dimensions) measure: GROSS MOTOR FUNCTION MEASURE 88 (D and E dimensions) measure: GROSS MOTOR FUNCTION MEASURE 88 (D and E dimensions) measure: GROSS MOTOR FUNCTION MEASURE 88 (D and E dimensions) measure: Modified Ashworth Scale (MAS) measure: Modified Ashworth Scale (MAS) measure: Modified Ashworth Scale (MAS) measure: Modified Ashworth Scale (MAS) measure: 6 Minute Walking Test (6MWT) measure: 6 Minute Walking Test (6MWT) measure: 6 Minute Walking Test (6MWT) measure: 6 Minute Walking Test (6MWT) measure: Dynamometry measure: Dynamometry measure: Dynamometry measure: Dynamometry measure: Mini-Balance Evaluation System Test measure: Mini-Balance Evaluation System Test measure: Mini-Balance Evaluation System Test measure: Mini-Balance Evaluation System Test measure: Cerebral Palsy Quality of Life questionnaire (CP-QOL) measure: Cerebral Palsy Quality of Life questionnaire (CP-QOL) measure: Cerebral Palsy Quality of Life questionnaire (CP-QOL) sex: ALL minimumAge: 8 Years maximumAge: 14 Years stdAges: CHILD facility: María José Díaz Arribas city: Madrid zip: 28040 country: Spain lat: 40.4165 lon: -3.70256 hasResults: False
<\|newrecord\|> nctId: NCT06330298 id: 202000479 briefTitle: Improving Social Cognition and Social Behaviour in Various Brain Disorders acronym: T-ScEmo4ALL overallStatus: RECRUITING date: 2021-05-31 date: 2025-01-31 date: 2025-01-31 date: 2024-03-26 date: 2024-04-16 name: University Medical Center Groningen class: OTHER briefSummary: Impairments in aspects of social cognition are disorder-transcending: these have been demonstrated in various neurological disorders, such as traumatic brain injury (TBI), stroke, brain tumours (both low grade glioma's and meningioma's) and multiple sclerosis (MS). Social cognition involves processing of social information, in particular the abilities to perceive social signals, understand others and respond appropriately (Adolphs 2001). Crucial aspects of social cognition are the recognition of facial expressions of emotions, perspective taking (also referred to as mentalizing or Theory of Mind), and empathy. Impairments in social cognition can have a large negative impact on self-care, communication, social and professional functioning, and thus on quality of life of patients.
Recently, a first multi-faceted treatment for social cognitive impairments in TBI was developed and evaluated; T-ScEmo (Training Social Cognition and Emotion). T-ScEmo turned out to be effective in reducing social cognitive symptoms and improving daily life social functioning in this particular group, with effects lasting over time (Westerhof-Evers et al, 2017, 2019).
Unfortunately, up till now there are no evidence based, transdiagnostic treatment possibilities available for these impeding social cognition impairments in neurological patient groups, other than TBI. Therefore the aim of the present study is to investigate whether T-ScEmo is effective for social cognition disorders in patients with different neurological impairments, such as stroke (including subarachnoidal haemorrhage (SAH)), brain tumours, MS, infection (meningitis, encephalitis) and other. The secondary objective is to determine which patient related factors are of influence on treatment effectiveness. In short, hopefully this study can contribute to a treatment possibility for social cognition disorders for all patients with various neurological disorders.
It is expected that T-ScEmo will be effective for various neurological disorders, based on previous research of Westerhof-Evers et al. (2017, 2019). Since social cognition disorders within patients with traumatic brain injury do all have the same ethiology it is expected that the treatment will show the same effects for patients with various neurological disorders. Therefore it is expected that patients will improve on social cognition, social participation and quality of life and social behaviour, that these results will last over time. conditions: Stroke conditions: Multiple Sclerosis conditions: Brain Tumor studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Experimental condition T0, baseline measurement at point of inclusion (at least \> 6 months post-acute injuries) T1, post measurement within 2 weeks after treatment T2, follow-up measurement within 3 - 5 months after treatment
Waiting list condition T0, baseline measurement at point of inclusion (at least \> 6 months post-acute injuries) T1, post measurement within 3 months after T0 T2, follow-up measurement within 3 - 5 months after T1
TBI group T1, post measurement within 2 weeks after treatment T2, follow-up measurement within 3 - 5 months after treatment
The participating patients are randomly allocated into two groups: an experimental condition and a waiting list condition.
In addition, a group of patients with Traumatic Brain Injury will receive T-ScEmo following regular care. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The neuropsychologist who leads T1 and T2 measurements will be masked for the fact of which patient will be draw in which clinical condition (experimental group or control group), however this cannot be guaranteed since patients may talk about their experience. whoMasked: INVESTIGATOR count: 84 type: ESTIMATED name: Treatment social cognition and emotion regulation (T-ScEmo) measure: Change in social behaviour examined by proxy measure: Social cognition: Emotion recognition as assessed using the Eckman-60 faces test measure: Social cognition: Theory of Mind as assessed using the Happé cartoons test measure: Social cognition: Theory of Mind as assessed using the Faux Pas test measure: Social cognition: assessed using the Hailing Sentence Completion Test measure: Demographic information measure: Self-rated social behaviour as assessed using the Dysexecutive questionnaire Social Scales. measure: Self-rated social behaviour as assessed using the Interpersonal Reactivity Index measure: Self-rated social behaviour as assessed using The Dutch version of the BAFQ social scales measure: Proxy-rated social behaviour as assessed using the Interpersonal Reactivity Index measure: Proxy-rated social behaviour as assessed using the Socioemotional Dysfunction Scale measure: Proxy-rated social behaviour as assessed using the Dutch version of the BAFQ social scales measure: Alexithymia measure: Life satisfaction measure: (Social) participation as assessed using the Utrecht Scale for Evaluation of Rehabilitation measure: (Social) participation as assessed using the Impact on Participation and Autonomy scale measure: Mood and anxiety measure: Caregiving burden measure: Goal attainment measure: Executive functioning as assessed using the Controlled Oral Word Association Test measure: Executive functioning assessed using the Key Search Test measure: Verbal memory measure: Working memory measure: Language measure: Mental speed and attention as assessed using the Trail Making Test measure: Mental speed and attention as assessed using the Symbol Digit Modalities Test measure: Premorbid intelligence measure: Fatigue measure: Health limitations measure: Coping sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Deventer Hospital status: RECRUITING city: Deventer state: Overijssel zip: 7416SE country: Netherlands name: M.J.J. Gerritssen, dr. role: CONTACT lat: 52.255 lon: 6.16389 facility: University Medical Center Groningen status: RECRUITING city: Groningen zip: 9700VB country: Netherlands name: Amber Heegers, MSc. role: CONTACT phone: +3150 361 4666 email: a.heegers@umcg.nl lat: 53.21917 lon: 6.56667 hasResults: False
<\|newrecord\|> nctId: NCT06330285 id: e learning pgme/cpet briefTitle: Comparison of E-Learning and Face-to-Face Learning in Cardiopulmonary Exercise Test Training overallStatus: NOT_YET_RECRUITING date: 2024-03-22 date: 2024-06-15 date: 2024-08-15 date: 2024-03-26 date: 2024-03-26 name: Kayseri City Hospital class: OTHER_GOV name: TC Erciyes University briefSummary: The main purpose of this study is to compare the effect of teaching Cardiopulmonary Exercise Test (CPET) via e-learning and face-to-face to doctors receiving postgraduate medical education (PGME). conditions: Exercise Test conditions: Learning studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 50 type: ESTIMATED name: e-learning name: face to face learning measure: Open-Ended Achievement Test measure: Adult Motivation Scale measure: Distance Education Attitude Scale in Lifelong Learning measure: Cognitive Flexibility Scale measure: State and Trait Anxiety Scale sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06330272 id: UCeuma briefTitle: Accuracy of Spectrophotometry in Hypomineralized Lesions Treated With CPP-ACPF Dental Mousse: Clinical Study acronym: ASHLTDMCS overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-01 date: 2025-03 date: 2024-03-26 date: 2024-03-28 name: Meire Coelho Ferreira class: OTHER name: Fundação de Amparo à Pesquisa e Desenvolvimento Científico do Maranhão briefSummary: MIH is a condition with considerable prevalence in the child population. This structural defect, represented by a change in the color of the enamel, can be accompanied by structural loss and great sensitivity. Remineralizing agents have been used to strengthen compromised enamel. The objective of the study will be to measure the accuracy of a spectrophotometer (VITA Easyshade V) in determining the mineralization of IMH lesions by a CPP-ACPF dental mousse. conditions: Molar Incisor Hypomineralization studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: MIH lesions will receive prophylaxis with pumice stone before application of CPP-ACPF-based dental foam (Tooth Mousse PlusTM, GC Corporation, Tokyo, Japan).
The application of Tooth Mousse Plus to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush. The cream will remain on the surface for 1 minute. The application will be carried out once a week, for four consecutive weeks. primaryPurpose: TREATMENT masking: NONE count: 98 type: ESTIMATED name: Application of dental mousse based on CPP-ACPF measure: To measure the accuracy of a spectrophotometer (VITA Easyshade V) in determining the mineralization of IMH lesions by a CPP-ACPF dental mousse sex: ALL minimumAge: 7 Years maximumAge: 9 Years stdAges: CHILD facility: Josue Montello, Universidade Ceuma city: São Luis state: Maranhão zip: 65075-120 country: Brazil lat: -2.52972 lon: -44.30278 hasResults: False
<\|newrecord\|> nctId: NCT06330259 id: new AMH assay briefTitle: Does the AMH Concentration Depend on the Menstrual Cycle? acronym: AMH overallStatus: COMPLETED date: 2017-07-01 date: 2018-06-30 date: 2019-12-31 date: 2024-03-26 date: 2024-04-01 name: University of Basel class: OTHER name: Roche Diagnostics briefSummary: During two none subsequent natural menstrual cycles healthy female participants will be subjected every second day to blood sampling and 3D-ultrasound examinations. Together with four other key hormones the concentration of AMH (anti-Muellerian Hormone) will be measured in the serum. conditions: Reproductive Sterility studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ACTUAL name: menstrual cycle monitoring measure: AMH Elecsys Assay measure: Effect of handling of the serum on measured AMH concentrations measure: 3D ultrasound of both ovaries sex: FEMALE minimumAge: 18 Years maximumAge: 39 Years stdAges: ADULT facility: Christian De Geyter city: Basel zip: 4031 country: Switzerland lat: 47.55839 lon: 7.57327 hasResults: False
<\|newrecord\|> nctId: NCT06330246 id: IRB300005280 id: R01DK137784 type: NIH link: https://reporter.nih.gov/quickSearch/R01DK137784 briefTitle: O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease overallStatus: RECRUITING date: 2024-05-01 date: 2030-12-31 date: 2031-12-31 date: 2024-03-26 date: 2024-04-03 name: University of Alabama at Birmingham class: OTHER name: University of Texas Southwestern Medical Center name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: The goal of this trial is to test if colonization with the gut bacteria Oxalobacter formigenes leads to a reduction in urinary oxalate excretion in patients with calcium oxalate kidney stone disease.
The study will recruit adult participants with a history of calcium oxalate kidney stones who are not colonized with Oxalobacter formigenes.
Participants will
* ingest fixed diets containing low and moderately high amounts of oxalate for 4 days at a time
* collect urine, blood and stool samples during the fixed diets
* ingest a preparation of live Oxalobacter formigenes to induce colonization with Oxalobacter formigenes conditions: Kidney Stone conditions: Kidney Calculi conditions: Urolithiasis conditions: Urolithiasis, Calcium Oxalate conditions: Nephrolithiasis conditions: Nephrolithiasis, Calcium Oxalate conditions: Oxalate Urolithiasis conditions: Oxaluria studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SEQUENTIAL primaryPurpose: BASIC_SCIENCE masking: NONE count: 40 type: ESTIMATED name: Low oxalate fixed diets pre-colonization name: Moderately high oxalate fixed diets pre-colonization name: Colonization with Oxalobacter formigenes name: Low oxalate fixed diets post-colonization name: Moderately high oxalate fixed diets post-colonization measure: Change in urinary oxalate excretion following colonization with Oxalobacter formigenes measure: Sustainability of colonization with Oxalobacter formigenes sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama at Birmingham status: RECRUITING city: Birmingham state: Alabama zip: 35294 country: United States name: Sonia Fargue, PhD role: CONTACT phone: 205-975-6932 email: sfargue@uab.edu name: Research Coordinator role: CONTACT phone: 2059345712 email: kidneystone@uabmc.edu name: Sonia Fargue, PhD role: PRINCIPAL_INVESTIGATOR lat: 33.52066 lon: -86.80249 facility: UTSW status: RECRUITING city: Dallas state: Texas zip: 75390 country: United States name: Naim Maalouf, MD role: CONTACT email: Naim.Maalouf@UTSouthwestern.edu name: Esperanza Jackson role: CONTACT email: Esperanza.Jackson@UTSouthwestern.edu name: Naim Maalouf, MD role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 hasResults: False
<\|newrecord\|> nctId: NCT06330233 id: YJiang briefTitle: Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-04-07 date: 2026-12-31 date: 2024-03-26 date: 2024-03-26 name: Zhejiang Chinese Medical University class: OTHER_GOV name: The First Affiliated Hospital of Zhejiang Chinese Medical University briefSummary: This study is designed to provide the treatment plan for moxibustion for diabetic peripheral neuropathy (DPN) and provide a reference for clinical moxibustion for DPN. The patients will be randomly assigned to three clinical centers each center 44, then they will be distributed equally into 4 groups, which include the conventional treatment group and the moxibustion different minutes (5 minutes, 10 minutes, 15 minutes) per point group. The conventional treatment group will receive mecobalamin tablets and alpha-lipoic acid tablets for four weeks in conjunction with the patient's daily treatment (basal drug treatment for patients with combined hypertension and hyperlipidaemia). The frequency of moxibustion treatment is twice a week for 4 weeks. The outcomes were evaluated in the baseline period (the day before grouping), the treatment period (end of the 8th treatment) and the follow-up period (2 weeks after the end of treatment). The results of this study are expected to confirm the optimal amount of moxibustion for the treatment of diabetic peripheral neuralgia and to observe the efficacy of moxibustion in the treatment of diabetic peripheral neuralgia. It provides a reference for the clinical therapeutic operation standardization of moxibustion. conditions: Diabetic Peripheral Neuropathy conditions: Pain conditions: Moxibustion conditions: Randomized Controlled Trial studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 132 type: ESTIMATED name: Moxibustion measure: Electrophysiological examination of the tibial nerve of the lower limb measure: Electrophysiological examination of the peroneal nerve of the lower limb measure: Total clinical effectiveness measure: Toronto Clinical Scoring System measure: Visual Analogue Scale measure: Traditional Chinese Medicine Syndrome Score Scale measure: regional temperature testing measure: infrared thermography testing sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06330220 id: 2010-015-1161 briefTitle: Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity overallStatus: COMPLETED date: 2021-02-10 date: 2022-02-28 date: 2022-02-28 date: 2024-03-26 date: 2024-03-26 name: Seoul National University Hospital class: OTHER briefSummary: Although the number of wet AMD patients with the better visual acuity is increasing, the visual improvement in patients with the better vision may not be so significant after anti-vascular endothelial growth factor (VEGF) treatments because of 'ceiling effect'. The aim of current study is to investigate the improvement of visual function after aflibercept treatments using microperimetry in wet AMD patients with the better baseline visual acuity (≥20/40). conditions: Age-Related Macular Degeneration studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ACTUAL name: Aflibercept Injection [Eylea] measure: Retinal sensitivity change after aflibercept treatment using microperimetry in wet age-related macular degeneration patients measure: The correlation of OCT and OCT angiography parameters with retinal sensitivity change measured by microperimetry sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital city: Seoul zip: 03080 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
<\|newrecord\|> nctId: NCT06330207 id: IRB202301471 id: K99DE031723 type: NIH link: https://reporter.nih.gov/quickSearch/K99DE031723 briefTitle: An Emergency Department (ED) Provider Centered Intervention for Non-Traumatic Dental Condition Management (NTDC) overallStatus: NOT_YET_RECRUITING date: 2025-08-01 date: 2027-02-01 date: 2027-08-01 date: 2024-03-26 date: 2024-03-26 name: University of Florida class: OTHER name: National Institute of Dental and Craniofacial Research (NIDCR) briefSummary: The overall objective of this proposal is to understand the barriers and facilitators to non-traumatic dental condition (NTDC) management in the emergency department (ED) through quantitative and qualitative methods. The first aim will determine the national variation in NTDC prescribing in the ED and subsequent ED/urgent care revisits and hospitalizations within 30-days of an index ED visit. Using national electronic health records and integrated claims datasets and a random effects model, we will identify factors associated with prescribing for NTDC and variation at the patient, provider, hospital and state levels. The second aim identifies ED providers' perceived barriers and facilitators to the management of NTDC in the ED. Using individual in depth interviews, ED providers (physicians, advanced practice providers) will identify the facilitators and barriers to management and prescribing for NTDC in the ED. conditions: Emergency Department Visit conditions: Odontalgia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 60 type: ESTIMATED name: Clinical decision support tool measure: Acceptability and feasibility measure: Prescribing behavior measure: Pilot trial outcomes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06330194 id: AID-study briefTitle: Next Generation Advanced Insulin Delivery System in Adults With Diabetes and Advanced Renal Disease overallStatus: RECRUITING date: 2024-04-18 date: 2024-12-31 date: 2024-12-31 date: 2024-03-26 date: 2024-04-22 name: Steno Diabetes Center Copenhagen class: OTHER name: Rigshospitalet, Denmark briefSummary: The goal of this this randomized, clinical trial is to test an automated insulin delivery system (AID) in people with type 1 or type 2 diabetes who are on hemodialysis, peritoneal dialysis, or have advanced chronic kidney disease (CKD).
The main objective is:
• To test if the AID is superior in regulating blood sugar levels compared with usual care in patients with advanced renal disease
Secondary objectives are:

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.